Table 3.
Presence of anti-SARS-CoV-2 at time of admission to the hospital and 1 week after admission (95% confidence interval)
| % seropositive | Roche Ig-N | Abbott IgG-N | Euro NCP IgG-N | Mikrogen IgG-N | Maglumi IgG-N/S | Diasorin IgG-S | Euro S1 IgG-S |
|---|---|---|---|---|---|---|---|
| At time of admission (n = 76) | 34.2% (26.0–43.6) | 30.3% (22.4–39.5) | 36.8% (28.3–46.3) | 32.9% (24.7–42.2) | 28.9% (21.2–38.1) | 21.1% (14.4–29.7) | 21.1% (14.4–29.7) |
| Critical (n = 23) | 26.1% (13.9–43.3) | 30.4% (17.3–47.7) | 39.1% (22.1–59.3) | 39.1% (22.1–59.3) | 30.4% (17.3–47.7) | 21.7% (10.7–38.7) | 17.4% (6.4–37.7) |
| Non-critical (n = 53) | 37.7% (25.9–51.2) | 30.2% (19.5–43.6) | 35.8% (24.3–49.3) | 30.2% (19.5–43.6) | 28.3% (17.9–41.7) | 20.8% (11.8–33.6) | 22.6% (13.3–35.7) |
| After 1 week (n = 41)a | 92.7% (79.9–98.2) | 95.1% (83.0–99.5) | 92.7% (79.9–98.2) | 92.7% (79.9–98.2) | 90.2% (76.9–96.7) | 85.4% (71.2–93.5) | 92.7% (79.9–98.2) |
| At admission | 26.8% (15.6–42.0) | 26.8% (15.6–42.0) | 31.7% (19.5–47.1) | 31.7% (19.5–47.1) | 26.8% (15.6–42.0) | 19.5% (10.0–34.3) | 17.1% (8.2–31.6) |
| After 1 week if negative | 27/30 (90.0%) (73.6–97.3) |
28/30 (93.3%) (77.6–0.99) |
25/28 (89.3%) (72.0–97.1) |
25/28 (89.3%) (72.0–97.1) |
25/31 (80.6%) (63.4–91.2) |
27/33 (81.8%) (65.2–91.8) |
31/34 (91.2%) (76.3–97.8) |
a
Subgroup consisting of those patients for whom a sample was available.